Loading...
Docoh

Akebia Therapeutics (AKBA)

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Company profile

Ticker
AKBA
Exchange
Website
CEO
John Butler
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Akebia Therapeutics Securities Corporation • Akebia Europe Limited • Keryx Biopharmaceuticals, Inc. • ACCESS Oncology, Inc. • AOI Pharma, Inc. • AOI Pharmaceuticals, Inc. • Online Collaborative Oncology Group, Inc. • Accumin Diagnostics, Inc. • Neryx Biopharmaceuticals, Inc. • Keryx Biopharma UK Ltd. ...

AKBA stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 146.98M 146.98M 146.98M 146.98M 146.98M 146.98M
Cash burn (monthly) 10.22M 8.5M (no burn) 12.14M 10.22M 14.28M
Cash used (since last report) 30.27M 25.18M n/a 35.93M 30.26M 42.28M
Cash remaining 116.71M 121.8M n/a 111.05M 116.72M 104.7M
Runway (months of cash) 11.4 14.3 n/a 9.2 11.4 7.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Aug 22 Steven Keith Burke Common Stock Sell Dispose S No No 0.3625 1,147 415.79 418,016
8 Jun 22 Ron Frieson Common Stock Grant Acquire A No No 0 13,700 0 13,700
8 Jun 22 Ron Frieson Stock Option Common Stock Grant Acquire A No No 0.45 20,100 9.05K 20,100
8 Jun 22 Adams Adrian Common Stock Grant Acquire A No No 0 13,700 0 104,800
8 Jun 22 Adams Adrian Stock Option Common Stock Grant Acquire A No No 0.45 20,100 9.05K 20,100
8 Jun 22 Gilman Steven C Common Stock Grant Acquire A No No 0 13,700 0 57,130
8 Jun 22 Gilman Steven C Stock Option Common Stock Grant Acquire A No No 0.45 20,100 9.05K 20,100
8 Jun 22 Rogers Michael W Common Stock Grant Acquire A No No 0 13,700 0 66,029
8 Jun 22 Rogers Michael W Stock Option Common Stock Grant Acquire A No No 0.45 20,100 9.05K 20,100
31.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 95 129 -26.4%
Opened positions 21 24 -12.5%
Closed positions 55 23 +139.1%
Increased positions 17 39 -56.4%
Reduced positions 34 42 -19.0%
13F shares Current Prev Q Change
Total value 52.38M 58.6M -10.6%
Total shares 57.64M 81.31M -29.1%
Total puts 124.6K 3.16M -96.1%
Total calls 294.51K 5.35M -94.5%
Total put/call ratio 0.4 0.6 -28.4%
Largest owners Shares Value Change
Vanguard 16.26M $5.74M +12.9%
Acadian Asset Management 7.34M $2.59M NEW
Millennium Management 5.35M $1.89M +103.4%
Satter Management 4.65M $1.64M 0.0%
BLK Blackrock 4.34M $1.53M -68.9%
FHI Federated Hermes 1.99M $702K -2.0%
Geode Capital Management 1.62M $571K -48.7%
Renaissance Technologies 1.48M $523K +47.7%
HRT Financial 1.1M $389K +4268.1%
Aqr Capital Management 862.17K $304K +367.4%
Largest transactions Shares Bought/sold Change
STT State Street 573.88K -10.91M -95.0%
BLK Blackrock 4.34M -9.62M -68.9%
Acadian Asset Management 7.34M +7.34M NEW
JPM JPMorgan Chase & Co. 7.22K -4.25M -99.8%
Millennium Management 5.35M +2.72M +103.4%
Dimensional Fund Advisors 782.68K -1.88M -70.7%
Vanguard 16.26M +1.86M +12.9%
Geode Capital Management 1.62M -1.54M -48.7%
Orchard Capital Managment 251.83K -1.51M -85.7%
NTRS Northern Trust 360.53K -1.32M -78.5%

Financial report summary

?
Management Discussion
  • Product Revenue, Net. Net product revenue is derived from sales of our only commercial product in the United States, Auryxia. We distribute our product principally through a limited number of wholesale distributors as well as certain specialty pharmacy providers. Net product revenue was $43.7 million for the three months ended June 30, 2022, compared to $33.0 million for the three months ended June 30, 2021. The increase was primarily due to pricing and improved payer mix.
  • License, Collaboration and Other Revenue. License, collaboration and other revenue was $83.1 million for the three months ended June 30, 2022 compared to $20.0 million for the three months ended June 30, 2021. On June 30, 2022, we and Otsuka entered into the Termination Agreement, which, among other things, terminated the cost sharing arrangement under the Otsuka collaboration agreement for the United States, or the Otsuka U.S. Agreement, and the Otsuka collaboration agreement for certain territories outside the United States, or the Otsuka International Agreement. During the three months ended June 30, 2022, we recognized $55.0 million in collaboration revenue related to a payment to be received pursuant to the terms of the Termination Agreement with Otsuka, $15.5 million related to previously deferred revenue as of the date of termination and $9.6 million of non-cash consideration related to Otsuka's obligations to complete certain agreed upon clinical activities related to the Phase 3b clinical trial of vadadustat Otsuka is conducting, or the MODIFY Study, in accordance with the current study protocol, at its own cost and expense. Refer to Note 4 in this Quarterly Report on Form 10-Q for further details. We will not recognize any future revenue under the Otsuka U.S. Agreement or the Otsuka International Agreement. We recognized $18.5 million in collaboration revenue for the three months ended June 30, 2021 from our cost sharing arrangement under the Otsuka U.S. Agreement and the Otsuka International Agreement, as well as royalty revenue under our collaboration agreement with MTPC.
  • Cost of Goods Sold - Product. Cost of goods sold of $9.6 million for the three months ended June 30, 2022 consisted of costs associated with the manufacturing of Auryxia and supply of Vafseo to MTPC for commercial sale in Japan, and $2.1 million related to excess and obsolescence reserves associated with inventory.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: Allergy, beneficiary, consecutive, Consortium, CPRA, disapproved, Exit, extracorporeal, hypoxemia, invasive, lifted, membrane, missed, nonrefundable, omicron, Ordinal, outlined, outpace, Paediatric, penalizing, Postemployment, prespecified, progressed, qualitative, quantitative, regain, reoccur, RionaTM, saved, score, split, Switzerland, timeframe, titled, unnecessarily, unnecessary, untreated, variant, ventilation, virtue, VSTAT
Removed: admission, Aktiengesellschaft, Animal, assured, BlackRock, buy, chosen, complication, constitutionality, creditable, credited, Directive, discrete, divisional, dosed, enactment, GmbH, heard, inseverable, Inspectional, insured, interdependence, interrelationship, invoiced, lessen, lessening, leveraging, located, mandate, minimal, move, nephrology, onset, postpone, postponed, preserve, prioritization, reached, redundant, reimbursable, relaxing, repeal, reply, Resiliency, resumption, Roadmap, standing, temporarily, unclear, undermine

Patents

Utility
Prolyl hydroxylase inhibitors and methods of use
30 Aug 22
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Utility
Compositions and methods for treating anemia
10 May 22
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Utility
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
8 Mar 22
Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids.
Utility
Solid Forms of {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC Acid, Compositions, and Uses Thereof
10 Feb 22
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Utility
Benzimidazole Derivative for Use In the Treatment of Inflammatory Disorders
2 Dec 21
Inventors: Michael Rabinowitz, Hariharan Venkatesan, Mark D. Rosen